James Doogue

There Was One Excess Death Per 6,250 Booster Jabs across all ages. The report's author says the risk-benefit ratio does not support mandatory mass vaccine rollout.

The study was published in EconPapers, authored by John Gibson, Professor in the Department of Economics at the University of Waikato, Hamilton, New Zealand.
https://econpapers.repec.org/RePEc:wai:econwp:22/11

In his paper, ‘The Rollout of COVID-19 Booster Vaccines is Associated with Rising Excess Mortality in New Zealand’, Prof. Gibson stated:

"The ratio of vaccine risk to benefits likely has swung more towards risk than during the original randomised trials, due to dose-dependent adverse events and to fixation of immune responses on a variant no longer circulating.

"In light of an unsatisfactory risk-evidence situation, aggregate weekly data on excess mortality in New Zealand are used here to study the impacts of rolling out booster doses.

"The age groups most likely to use boosters had 7-10 percentage point rises in excess mortality rates as boosters were rolled out while the age group that is mostly too young for boosters saw no rise in excess mortality.”

FDA Advisory Panel Voted 16 - 3 Against Mass Booster Rollout But The FDA Ignored Them. https://www.forbes.com/sites/jemimamcevoy/2021/09/17/fda-advisory-panel-recommends-against-pfizer-covid-boosters-except-for-people-over-65/

In September 2021 an advisory panel of experts outside of the US Food and Drug Administration ("FDA”) voted 16-2 against the widespread use of Covid injection boosters due to a lack of safety data and doubts about the benefits of mass boosting over targeted approaches, Gibson noted.

After this vote was ignored and the FDA approved boosters for the general population, the top two officials in the FDA’s Office of Vaccines Research and Review resigned and criticised decision-making about the mass rollout of boosters.

This critique noted that if unnecessary boosting causes significant adverse reactions it may increase vaccine hesitancy more generally; a concern raised elsewhere that the potentially low benefits of Covid-19 vaccines relative to the costs borne by vaccinees (such as exposure to breakthrough infections and to vaccine adverse events) may undermine public confidence in other vaccination efforts (Godlee, 2020; Gibson, 2022a). Even the World Health Organisation argue that a vaccination strategy based on repeated booster doses of the original vaccine composition is unlikely to be appropriate or sustainable (WHO, 2022).

Several European countries have already restricted some mRNA vaccines to only those aged over 30 years due to these safety concerns.

Given this shift in the risk-benefit ratio, stronger evidence should underpin mass use of boosters but the opposite holds.

Posted by: Timothy Birdnow at 10:49 AM | Comments (3) | Add Comment
Post contains 427 words, total size 3 kb.